Showing 2051-2060 of 3223 results for "".
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- FDA Expands Emergency Use for Gilead’s Veklury to All Hospitalized COVID-19 Patientshttps://modernod.com/news/fda-expands-emergency-use-for-gileads-veklury-to-all-hospitalized-covid-19-patients/2478218/The FDA has broadened the scope of an existing emergency-use authorization (EUA) for Gilead Sciences’ Veklury (remdesivir) to include treatment of all hospitalized adult and paediatric patients with suspected or laboratory-confirmed COVID-19, regardless of the severity of their disease. In
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M
- American Academy of Optometry Foundation Announces the 2020 Alfred A. Rosenbloom Jr. Low Vision Residency Award Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-alfred-a-rosenbloom-jr-low-vision-residency-award-recipient/2478194/The American Academy of Optometry has announced that Carolyn N. Chakuroff, OD, MS, is this year’s recipient of the Alfred A. Rosenbloom Jr. Low Vision Residency Award. Dr. Chakuroff is a graduate of The Ohio State University College of Optometry and an Ocular Disease/Low Vision Rehabilitation res
- Alcon Kicks Off Global Social Media Campaignhttps://modernod.com/news/alcon-kicks-off-global-social-media-campaign/2478183/Alcon kicked off a global social media campaign, “Reasons to Love Lenses,” during Contact Lens Health Week taking place August 17–21. The new campaign raises consumer awareness of the benefits of contact lens wear. The campaign also reiterates the value of prescribing contact lenses for eye care
- Supreme Court to Hear Arguments on Pivotal Case That Decides Fate of ACA After Electionhttps://modernod.com/news/supreme-court-to-hear-arguments-on-pivotal-case-that-decides-fate-of-aca-after-election/2478180/The Supreme Court will hear oral arguments in a lawsuit over the constitutionality of the Affordable Care Act (ACA) on November 10, a week after the presidential election, according to a FierceHealthcare
- Alcon Broadens US Availability of MARLO Digital Platformhttps://modernod.com/news/alcon-broadens-us-availability-of-marlo-digital-platform/2478153/Alcon announced broader US availability of its MARLO digital platform offered within independent OD practice. The platform allows patients to order, reorder and track their Alcon contact lens order online and have their lenses shipped right to their doorstep, while keeping the relationship and re
- Alcon Canada introduces PRECISION1 Contact Lenseshttps://modernod.com/news/alcon-canada-introduces-precision1-contact-lenses/2478144/Alcon has launched the PRECISION1 daily disposable, silicone hydrogel (SiHy) contact lenses in Canada. Designed to address the common issues that cause 1-in-5 new wearers to discontinue contact lens within the first year (poor vision, comfort and handling issues1), Precision1 he
- Eli Lilly Starts Late-Stage Study of Neutralizing Antibody Against SARS-CoV-2 in Nursing Homeshttps://modernod.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/Eli Lilly announced the initiation of a phase 3 study investigating whether its antibody-based drug LY-CoV555 can help reduce the rate of SARS-CoV-2 infection and COVID-19 in long-term care facilities in the US. The company is developing the neutralizing IgG1 antibody, which
- EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/EyePoint Pharmaceuticals and ImprimisRx announced the signing of a commercial alliance for the joint promotion of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the United States.